XPH Quote, Financials, Valuation and Earnings

Invesco Biotechnology & Genome ETF has a net margin of -- compared to SPDR S&P Pharmaceuticals ETF's net margin of --. SPDR S&P Pharmaceuticals ETF's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.

SPDR S&P Pharmaceuticals ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Pharmaceuticals ETF has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe SPDR S&P Pharmaceuticals ETF is more attractive than Invesco Biotechnology & Genome ETF.

SPDR S&P Pharmaceuticals ETF has a beta of 0.626, which suggesting that the stock is 37.401% less volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.809, suggesting its less volatile than the S&P 500 by 19.078%.

SPDR S&P Pharmaceuticals ETF has a quarterly dividend of $0.10 per share corresponding to a yield of 1.47%. Invesco Biotechnology & Genome ETF offers a yield of 0.26% to investors and pays a quarterly dividend of $0.13 per share. SPDR S&P Pharmaceuticals ETF pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.

SPDR S&P Pharmaceuticals ETF quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. SPDR S&P Pharmaceuticals ETF's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, SPDR S&P Pharmaceuticals ETF's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Pharmaceuticals ETF is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.

Invesco Pharmaceuticals ETF has a net margin of -- compared to SPDR S&P Pharmaceuticals ETF's net margin of --. SPDR S&P Pharmaceuticals ETF's return on equity of -- beat Invesco Pharmaceuticals ETF's return on equity of --.

SPDR S&P Pharmaceuticals ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Pharmaceuticals ETF has higher upside potential than Invesco Pharmaceuticals ETF, analysts believe SPDR S&P Pharmaceuticals ETF is more attractive than Invesco Pharmaceuticals ETF.

SPDR S&P Pharmaceuticals ETF has a beta of 0.626, which suggesting that the stock is 37.401% less volatile than S&P 500. In comparison Invesco Pharmaceuticals ETF has a beta of 0.506, suggesting its less volatile than the S&P 500 by 49.427%.

SPDR S&P Pharmaceuticals ETF has a quarterly dividend of $0.10 per share corresponding to a yield of 1.47%. Invesco Pharmaceuticals ETF offers a yield of 1.21% to investors and pays a quarterly dividend of $0.27 per share. SPDR S&P Pharmaceuticals ETF pays -- of its earnings as a dividend. Invesco Pharmaceuticals ETF pays out -- of its earnings as a dividend.

SPDR S&P Pharmaceuticals ETF quarterly revenues are --, which are smaller than Invesco Pharmaceuticals ETF quarterly revenues of --. SPDR S&P Pharmaceuticals ETF's net income of -- is lower than Invesco Pharmaceuticals ETF's net income of --. Notably, SPDR S&P Pharmaceuticals ETF's price-to-earnings ratio is -- while Invesco Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Pharmaceuticals ETF is -- versus -- for Invesco Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.

SPDR S&P Health Care Equipment ETF has a net margin of -- compared to SPDR S&P Pharmaceuticals ETF's net margin of --. SPDR S&P Pharmaceuticals ETF's return on equity of -- beat SPDR S&P Health Care Equipment ETF's return on equity of --.

SPDR S&P Pharmaceuticals ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Health Care Equipment ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Pharmaceuticals ETF has higher upside potential than SPDR S&P Health Care Equipment ETF, analysts believe SPDR S&P Pharmaceuticals ETF is more attractive than SPDR S&P Health Care Equipment ETF.

SPDR S&P Pharmaceuticals ETF has a beta of 0.626, which suggesting that the stock is 37.401% less volatile than S&P 500. In comparison SPDR S&P Health Care Equipment ETF has a beta of 1.055, suggesting its more volatile than the S&P 500 by 5.483%.

SPDR S&P Pharmaceuticals ETF has a quarterly dividend of $0.10 per share corresponding to a yield of 1.47%. SPDR S&P Health Care Equipment ETF offers a yield of 0.07% to investors and pays a quarterly dividend of $0.02 per share. SPDR S&P Pharmaceuticals ETF pays -- of its earnings as a dividend. SPDR S&P Health Care Equipment ETF pays out -- of its earnings as a dividend.

SPDR S&P Pharmaceuticals ETF quarterly revenues are --, which are smaller than SPDR S&P Health Care Equipment ETF quarterly revenues of --. SPDR S&P Pharmaceuticals ETF's net income of -- is lower than SPDR S&P Health Care Equipment ETF's net income of --. Notably, SPDR S&P Pharmaceuticals ETF's price-to-earnings ratio is -- while SPDR S&P Health Care Equipment ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Pharmaceuticals ETF is -- versus -- for SPDR S&P Health Care Equipment ETF. Usually stocks with elevated PS ratios are considered overvalued.

SPDR S&P Health Care Services ETF has a net margin of -- compared to SPDR S&P Pharmaceuticals ETF's net margin of --. SPDR S&P Pharmaceuticals ETF's return on equity of -- beat SPDR S&P Health Care Services ETF's return on equity of --.

SPDR S&P Pharmaceuticals ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Health Care Services ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Pharmaceuticals ETF has higher upside potential than SPDR S&P Health Care Services ETF, analysts believe SPDR S&P Pharmaceuticals ETF is more attractive than SPDR S&P Health Care Services ETF.

SPDR S&P Pharmaceuticals ETF has a beta of 0.626, which suggesting that the stock is 37.401% less volatile than S&P 500. In comparison SPDR S&P Health Care Services ETF has a beta of 1.016, suggesting its more volatile than the S&P 500 by 1.637%.

SPDR S&P Pharmaceuticals ETF has a quarterly dividend of $0.10 per share corresponding to a yield of 1.47%. SPDR S&P Health Care Services ETF offers a yield of 0.28% to investors and pays a quarterly dividend of $0.06 per share. SPDR S&P Pharmaceuticals ETF pays -- of its earnings as a dividend. SPDR S&P Health Care Services ETF pays out -- of its earnings as a dividend.

SPDR S&P Pharmaceuticals ETF quarterly revenues are --, which are smaller than SPDR S&P Health Care Services ETF quarterly revenues of --. SPDR S&P Pharmaceuticals ETF's net income of -- is lower than SPDR S&P Health Care Services ETF's net income of --. Notably, SPDR S&P Pharmaceuticals ETF's price-to-earnings ratio is -- while SPDR S&P Health Care Services ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Pharmaceuticals ETF is -- versus -- for SPDR S&P Health Care Services ETF. Usually stocks with elevated PS ratios are considered overvalued.